| Autor: |
Maerevoet, Marie Zijlstra, Josee M. Follows, George and Casasnovas, Rene-Olivier Vermaat, J. S. P. Kalakonda, Nagesh and Goy, Andre Choquet, Sylvain Van den Neste, Eric Hill, Brian and Thieblemont, Catherine Cavallo, Federica De la Cruz, Fatima and Kuruvilla, John Hamad, Nada Jaeger, Ulrich Caimi, Paolo and Gurion, Ronit Warzocha, Krzysztof Bakhshi, Sameer and Sancho, Juan-Manuel Schuster, Michael Egyed, Miklos Offner, Fritz Vassilakopoulos, Theodoros P. Samal, Priyanka Ku, Matthew Ma, Xiwen Corona, Kelly Chamoun, Kamal Shah, Jatin Shacham, Sharon Kauffman, Michael G. Canales, Miguel |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Popis: |
Patients with RR DLBCL who have received >= 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patients with RR DLBCL and demonstrated an overall response rate (ORR) of 29.1% with median duration of response (DOR) of 9.3 months. The analyses described here evaluated a number of subpopulations in order to understand how response correlates with survival outcomes in order to identify patients who could most optimally benefit from selinexor treatment. Median age was 67 years; 44.8% of patients were >= 70 years of age. The median OS was 9.0 months (95% CI 6.2, 13.7) at a median follow-up of 14.8 months. The median OS was not reached in patients with a CR or PR, while patients who did not respond have a median OS of 4.9 months (p < 0.0001). Patients < 70 years had an OS of 11.1 months compared with 7.8 months in patients >= 70 years. Among patients with or without prior ASCT, the median OS was 10.9 and 7.8 months, respectively. Among patients with disease refractory to the most recent DLBCL treatment regimen, the median OS was 7.0 months compared with 11.1 months for disease not refractory to the most recent treatment. In a patient population in which survival is expected to be < 6 months, treatment with single-agent oral selinexor was associated with a median survival of 9 months. Increased median OS observed in patients responding to selinexor was consistent across subgroups regardless of age, prior ASCT therapy, or refractory status. Randomized studies of selinexor in combination with a variety of other anti-DLBCL agents are planned. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
